 An analysis of Phase 3 data presented by Biogen Inc NASDAQ: BIIB and Eisai Co Ltd OTC: ESALY of its Alzheimers therapy Aduhelm aducanumab showed the treatment slowed cognitive, functional, and behavioral decline in the early stages of the disease. Treatment effects were exhibited across all three cognitive and three functional domains measured by Clinical Dementia Rating-Sum of Boxes CDR-SB, the EMERGE studys primary endpoint. 